1
|
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22:1378-1390. [PMID: 34529931 DOI: 10.1016/s1470-2045(21)00428-9] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Revised: 07/06/2021] [Accepted: 07/14/2021] [Indexed: 01/05/2023]
Abstract
BACKGROUND CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induction and consolidation in patients with autologous stem-cell transplant (ASCT)-eligible newly diagnosed multiple myeloma. In part 2, we compared daratumumab maintenance versus observation only. METHODS CASSIOPEIA is a two-part, open-label, randomised, phase 3 trial of patients aged 18-65 years with newly diagnosed multiple myeloma and Eastern Cooperative Oncology Group performance status 0-2, done in 111 European academic and community practice centres. In part 1, patients were randomly assigned (1:1) to induction and consolidation with D-VTd or VTd. Patients still on study who had a partial response or better were randomly assigned (1:1) by an interactive web-response system to daratumumab 16 mg/kg intravenously every 8 weeks (a reduced frequency compared with standard daratumumab long-term dosing) or observation only for up to 2 years. Stratification factors were induction treatment and depth of response in part 1. The part 2 primary endpoint was progression-free survival from second randomisation. This preplanned interim analysis of progression-free survival was done after 281 events and shall be considered the primary analysis of progression-free survival. Sponsor personnel and designees who were involved in the analysis were masked to treatment group until the independent data monitoring committee recommended that the preplanned interim analysis be considered the main analysis of progression-free survival in part 2. Otherwise, treatment assignments were unmasked. The interaction between induction and consolidation and maintenance was tested at a two-sided significance level of 0·05 by a stratified Cox regression model that included the interaction term between maintenance treatment and induction and consolidation treatment. Efficacy analyses were done in the maintenance-specific intention-to-treat population, which comprised all patients who underwent second randomisation. Safety was analysed in all patients in the daratumumab group who received at least one dose and all patients randomly assigned to observation only. This trial is registered with ClinicalTrials.gov, NCT02541383. Long-term follow-up is ongoing and the trial is closed to new participants. FINDINGS Between May 30, 2016, and June 18, 2018, 886 patients (458 [84%] of 543 in the D-VTd group and 428 [79%] of 542 in the VTd group) were randomly assigned to daratumumab maintenance (n=442) or observation only (n=444). At a median follow-up of 35·4 months (IQR 30·2-39·9) from second randomisation, median progression-free survival was not reached (95% CI not evaluable [NE]-NE) with daratumumab versus 46·7 months (40·0-NE) with observation only (hazard ratio 0·53, 95% CI 0·42-0·68, p<0·0001). A prespecified analysis of progression-free survival results showed a significant interaction between maintenance and induction and consolidation therapy (p<0·0001). The most common grade 3 or 4 adverse events were lymphopenia (16 [4%] of 440 patients in the daratumumab group vs eight [2%] of 444 patients in the observation-only group), hypertension (13 [3%] vs seven [2%]), and neutropenia (nine [2%] vs ten [2%]). Serious adverse events occurred in 100 (23%) patients in the daratumumab group and 84 (19%) patients in the observation-only group. In the daratumumab group, two adverse events led to death (septic shock and natural killer-cell lymphoblastic lymphoma); both were related to treatment. INTERPRETATION Daratumumab maintenance every 8 weeks for 2 years significantly reduced the risk of disease progression or death compared with observation only. Longer follow-up and other ongoing studies will shed further light on the optimal daratumumab-containing post-ASCT maintenance treatment strategy. FUNDING Janssen Research & Development, the Intergroupe Francophone du Myélome, and the Dutch-Belgian Cooperative Trial Group for Hematology Oncology.
Collapse
Affiliation(s)
- Philippe Moreau
- Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.
| | - Cyrille Hulin
- Bordeaux University Hospital Center, Bordeaux, France
| | - Aurore Perrot
- Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
| | - Bertrand Arnulf
- Hematology and Oncology, Hôpital Saint Louis, APHP, Paris, France
| | | | | | - Marie C Béné
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Sonja Zweegman
- Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Hélène Caillon
- Biochemistry Laboratory, Nantes University Hospital, Nantes, France
| | - Denis Caillot
- Dijon University Hospital, Hôpital du Bocage, Dijon, France
| | - Jill Corre
- Unité de Genomique du Myélome, IUC-T Oncopole, Toulouse, France
| | - Michel Delforge
- Department of Hematology, University Hospital Leuven, Leuven, Belgium
| | - Thomas Dejoie
- Biochemistry Laboratory, Nantes University Hospital, Nantes, France
| | - Chantal Doyen
- Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
| | - Thierry Facon
- Service des Maladies du Sang, Hôpital Claude Huriez, Lille, France
| | - Cécile Sonntag
- University Hospital, Hôpital Hautepierre, Strasbourg, France
| | - Jean Fontan
- University Hospital Jean Minjoz, Besancon, France
| | - Mohamad Mohty
- Hematology and Cellular Therapy Department of Saint-Antoine Hospital, Sorbonne University, Paris, France
| | | | - Lionel Karlin
- Lyon University Hospital, Hematology Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
| | | | | | - Xavier Leleu
- Poitiers University Hospital, CHU la Milétrie, Poitiers, France
| | | | | | | | | | | | - Soraya Wuillème
- Hematology Biology, Nantes University Hospital, Nantes, France
| | | | - Cyrille Touzeau
- Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France
| | - Mourad Tiab
- Centre Hospitalier Départemental Vendée, La Roche sur Yon, France
| | | | - Nathalie Meuleman
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | | | | | | | | | | | | | - Réda Garidi
- Saint-Quentin Hospital Center, Saint Quentin, France
| | | | | | - Ke Zhang
- Janssen Research & Development, La Jolla, CA, USA
| | - Carla de Boer
- Janssen Research & Development, LLC, Leiden, Netherlands
| | - Sanjay Vara
- Janssen Research & Development, High Wycombe, UK
| | | | | | | | | | | |
Collapse
|
2
|
Debord C, Wuillème S, Eveillard M, Theisen O, Godon C, Le Bris Y, Béné MC. Flow cytometry in the diagnosis of mature B-cell lymphoproliferative disorders. Int J Lab Hematol 2021; 42 Suppl 1:113-120. [PMID: 32543070 DOI: 10.1111/ijlh.13170] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/27/2020] [Accepted: 01/31/2020] [Indexed: 12/19/2022]
Abstract
B-lineage lymphoproliferative disorders (LPD) are rather frequent diseases, associated with specific clinical or biological features but also sometimes of fortuitous discovery. Multiparameter flow cytometry plays a major role for a rapid diagnostic indication, on peripheral blood or bone marrow samples in most instances, guiding complementary analyses and allowing for the proper therapeutic management of patients. After describing the important pre-analytical precautions required for an adequate assessment, the immunophenotypic features of small-cell and large-cell lymphomas are described in this review. The ubiquitous expression of CD19 is a first mandatory gating step. A possible clonal proliferation is then suspected by the demonstration of surface immunoglobulin light chain restriction. The aberrant presence of CD5 allows to segregate chronic lymphocytic leukemia and mantle cell lymphoma in most cases. Other LPD exhibit specific immunophenotypic features. A table of useful markers and a decision tree are provided. Of note, immunophenotypic data should as much as possible be interpreted in an integrated manner, involving the patient's clinical and other biological features, and be completed by further chromosomal and/or molecular investigations.
Collapse
Affiliation(s)
- Camille Debord
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| | - Soraya Wuillème
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| | - Marion Eveillard
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| | - Olivier Theisen
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| | - Catherine Godon
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| | - Yanick Le Bris
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| | - Marie C Béné
- Hematology Biology Department, Nantes University Hospital and CRCINA, Nantes, France
| |
Collapse
|
3
|
Gillet B, Joram N, Bacchi VF, Thomas C, Béné MC, Wuillème S. Neisseria meningitidis inside neutrophils, revealing properdin deficiency. Int J Infect Dis 2020; 99:117-118. [PMID: 32717395 DOI: 10.1016/j.ijid.2020.07.040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 07/21/2020] [Accepted: 07/22/2020] [Indexed: 10/23/2022] Open
Affiliation(s)
- Benjamin Gillet
- Service d'Hématologie Biologique, Centre Hospitalier Universitaire, Nantes, France
| | - Nicolas Joram
- Service de Réanimation Pédiatrique, Centre Hospitalier Universitaire, Nantes, France
| | | | - Caroline Thomas
- Service d'Hématologie et Immunologie Pédiatrique, Centre Hospitalier Universitaire, Nantes, France
| | - Marie C Béné
- Service d'Hématologie Biologique, Centre Hospitalier Universitaire, Nantes, France
| | - Soraya Wuillème
- Service d'Hématologie Biologique, Centre Hospitalier Universitaire, Nantes, France.
| |
Collapse
|
4
|
Debord C, Bourcier J, Subiger F, Leclair F, Touzeau C, Gastinne T, Moreau A, Theisen O, Godon C, Robillard N, Le Bris Y, Béné MC, Wuillème S. Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. Ann Hematol 2020; 100:285-287. [PMID: 32193629 DOI: 10.1007/s00277-020-03989-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 03/08/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Camille Debord
- Hematology Biology, Nantes University Hospital, Nantes, France.
| | - Jessie Bourcier
- Oncohematology Clinic, Vendée Hospital Center, La Roche sur Yon, France
| | | | - François Leclair
- Pathology Department, Vendée Hospital Center, La Roche sur Yon, France
| | - Cyrille Touzeau
- Hematology Clinic, Nantes University Hospital, Nantes, France
| | - Thomas Gastinne
- Hematology Clinic, Nantes University Hospital, Nantes, France
| | - Anne Moreau
- Pathology Department, Nantes University Hospital, Nantes, France
| | - Olivier Theisen
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Catherine Godon
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Nelly Robillard
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Yannick Le Bris
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Marie C Béné
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Soraya Wuillème
- Hematology Biology, Nantes University Hospital, Nantes, France
| |
Collapse
|
5
|
Fournier E, Debord C, Soenen V, Trillot N, Gonzales F, Tintiller V, Terriou L, Derrieux C, Abou Chahla W, Paris C, Berthon C, Boyer T, Lambilliotte A, Boisseau P, Wuillème S, Fouassier M, Susen S, Preudhomme C, Duployez N. Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. Br J Haematol 2020; 189:e119-e122. [DOI: 10.1111/bjh.16543] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Elise Fournier
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
| | | | - Valérie Soenen
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
| | - Nathalie Trillot
- Department of Haemostasis and Transfusion CHU Lille Lille France
| | - Fanny Gonzales
- Department of Paediatric Haematology CHU Lille Lille France
| | | | - Louis Terriou
- Department of Internal Medicine and Clinical Immunology CHU Lille Lille France
| | - Coralie Derrieux
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
| | | | - Camille Paris
- Department of Haemostasis and Transfusion CHU Lille Lille France
| | - Céline Berthon
- Department of Clinical Haematology CHU Lille LilleFrance
- CNRS INSERM UMR 9020 – UMR‐S 1277 University of Lille LilleFrance
| | - Thomas Boyer
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
- Laboratory of Haematology CHU Amiens‐Picardie AmiensFrance
| | | | | | | | - Marc Fouassier
- Laboratory of Haematology CHU Nantes Nantes France
- Haemophilia Center CHU Nantes NantesFrance
| | - Sophie Susen
- Department of Haemostasis and Transfusion CHU Lille Lille France
- INSERM UMR 1011 Institut Pasteur de Lille University of Lille Lille France
| | - Claude Preudhomme
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
- CNRS INSERM UMR 9020 – UMR‐S 1277 University of Lille LilleFrance
| | - Nicolas Duployez
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
- CNRS INSERM UMR 9020 – UMR‐S 1277 University of Lille LilleFrance
| |
Collapse
|
6
|
Debord C, Robillard N, Theisen O, Gastinne T, Godmer P, Graveleau J, Le Gouill S, Luycx O, Tiab M, Loirat M, Lestang E, Wuillème S, Godon C, Eveillard M, Béné MC. CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms. Hematol Oncol 2018; 36:607-609. [PMID: 29656538 DOI: 10.1002/hon.2511] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 02/13/2018] [Accepted: 03/13/2018] [Indexed: 11/08/2022]
Affiliation(s)
- Camille Debord
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Nelly Robillard
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Olivier Theisen
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Thomas Gastinne
- Department of Hematology, Nantes University Hospital, Nantes, France
| | - Pascal Godmer
- Department of Hematology, Bretagne Atlantique Hospital, Vannes, France
| | - Julie Graveleau
- Department of Internal Medicine, St Nazaire Hospital, Saint-Nazaire, France
| | - Steven Le Gouill
- Department of Hematology, Nantes University Hospital, Nantes, France
| | - Odile Luycx
- Department of Hematology, Bretagne Sud Hospital, Lorient, France
| | - Mourad Tiab
- Department of Hematology, Vendée Hospital, La Roche sur Yon, France
| | - Marion Loirat
- Department of Internal Medicine, St Nazaire Hospital, Saint-Nazaire, France
| | - Elsa Lestang
- Department of Internal Medicine, St Nazaire Hospital, Saint-Nazaire, France
| | - Soraya Wuillème
- Hematology Biology, Nantes University Hospital, Nantes, France
| | - Catherine Godon
- Hematology Biology, Nantes University Hospital, Nantes, France
| | | | | |
Collapse
|
7
|
Béné MC, Le Bris Y, Robillard N, Wuillème S, Fouassier M, Eveillard M. Flow cytometry in hematological nonmalignant disorders. Int J Lab Hematol 2015; 38:5-16. [PMID: 26542092 DOI: 10.1111/ijlh.12438] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 07/20/2015] [Indexed: 12/31/2022]
Abstract
Multiparameter flow cytometry (MFC) has become an integral part of the diagnosis and classification of hematological malignancies. However, several nonmalignant or premalignant disorders may benefit from this technology in hematology laboratories. This review provides information on the normal immunophenotypic characteristics of peripheral blood leukocyte subsets and their modifications in several clinical conditions. The usefulness of MFC and the specific markers that can be investigated in hyperlymphocytosis, infection, hypereosinophilia, paroxysmal nocturnal hemoglobinuria, and large granular lymphocyte disorders is described. Mention is also made of the developments of MFC for analyses of red blood cells or platelets.
Collapse
Affiliation(s)
- M C Béné
- Hematology Biology, University Hospital of Nantes, Nantes, France
| | - Y Le Bris
- Hematology Biology, University Hospital of Nantes, Nantes, France
| | - N Robillard
- Hematology Biology, University Hospital of Nantes, Nantes, France
| | - S Wuillème
- Hematology Biology, University Hospital of Nantes, Nantes, France
| | - M Fouassier
- Hematology Biology, University Hospital of Nantes, Nantes, France
| | - M Eveillard
- Hematology Biology, University Hospital of Nantes, Nantes, France
| |
Collapse
|
8
|
Eveillard M, Delaunay J, Richebourg S, Lodé L, Garand R, Wuillème S, Duhoux F, Antoine-Poirel H, Godon C, Béné MC. The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica 2015; 100:e114-5. [PMID: 25740106 DOI: 10.3324/haematol.2014.121079] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
| | | | - Steven Richebourg
- Hematology Laboratory, University Hospital, Nantes, France Cytogenetics, CHU Québec Hôpital Saint Sacrement, Québec, Canada
| | - Laurence Lodé
- Hematology Laboratory, University Hospital, Nantes, France
| | - Richard Garand
- Hematology Laboratory, University Hospital, Nantes, France
| | | | - François Duhoux
- Hematologic Genetics, Clinique Universitaire Saint Luc, UCL, Brussels, Belgium
| | | | | | - Marie C Béné
- Hematology Laboratory, University Hospital, Nantes, France
| |
Collapse
|
9
|
Abstract
Plasma cells (PCs) are essentially characterized by the co-expression of CD138 and CD38, which allows their identification in flow cytometry in bone marrow (BM), peripheral blood, or cell suspensions from tissues. These terminally differentiated B-cells may lose the expression of surface CD19 and that of CD20 while retaining CD27. When malignant, they can gain a number of other markers such as CD28, CD33, CD56, or CD117 and lose CD27. Moreover, since each PC is only able to produce a single type of immunoglobulins (Igs), they display isotypic restriction and clonal malignant PCs can be further characterized by their homogeneous expression of either kappa or lambda light chains. In multiple myeloma (MM), such PC clones produce the Ig identified in plasma as an abnormal peak. In the BM where they essentially accumulate, these PCs may however display various immunophenotypes. The latter were explored in a two-way approach. Firstly, the various subsets delineated by the selective or common expression of CD19 together with combined CD56/CD28 were explored in normal and MM BM. Then, other aberrant markers’ expression was investigated, i.e., CD20, CD27, CD33, CD56, CD117. These data were compared to literature information. They underline the vast heterogeneity of MM PCs possibly accounting for the various answers to therapy of MM patients.
Collapse
Affiliation(s)
- Nelly Robillard
- Service d'Hématologie Biologique, Laboratoire de Biologie, CHU de Nantes , Nantes , France
| | - Soraya Wuillème
- Service d'Hématologie Biologique, Laboratoire de Biologie, CHU de Nantes , Nantes , France
| | - Philippe Moreau
- Service d'Hématologie Clinique, CHU de Nantes , Nantes , France
| | - Marie C Béné
- Service d'Hématologie Biologique, Laboratoire de Biologie, CHU de Nantes , Nantes , France
| |
Collapse
|
10
|
Robillard N, Béné MC, Moreau P, Wuillème S. A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J 2013; 3:e134. [PMID: 23955589 PMCID: PMC3763387 DOI: 10.1038/bcj.2013.33] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- N Robillard
- Laboratoire d'Hématologie, Institut de Biologie, CHU de Nantes, Nantes, France
| | | | | | | |
Collapse
|
11
|
Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95:1973-6. [PMID: 20634494 DOI: 10.3324/haematol.2010.023697] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Deletion of the 17p13 chromosomal region [del(17p)] is associated with a poor outcome in multiple myeloma. Most of the studies have targeted the TP53 gene for deletion analyses, although no study showed that this gene is the deletion target. In order to address this issue, we sequenced the TP53 gene in 92 patients with multiple myeloma at diagnosis, 54 with a del(17p) and 38 lacking del(17p). At least one mutation was found in 20 patients, all of them presenting a del(17p). The analysis of the mutation location showed that virtually all of them occurred in highly conserved domains involved in the DNA-protein interactions. In conclusion, we showed that 37% of the myeloma patients with del(17p) present a TP53 mutation versus 0% in patients lacking the del(17p). The prognostic significance of these mutations remains to be evaluated.
Collapse
Affiliation(s)
- Laurence Lodé
- Laboratoire d’Hématologie, University Hospital, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Robillard N, Wuillème S, Lodé L, Magrangeas F, Minvielle S, Avet-Loiseau H. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 2005; 19:2021-2. [PMID: 16167057 DOI: 10.1038/sj.leu.2403948] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
MESH Headings
- Aminoglycosides/therapeutic use
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antigens, CD/analysis
- Antigens, CD/biosynthesis
- Antigens, Differentiation, Myelomonocytic/analysis
- Antigens, Differentiation, Myelomonocytic/biosynthesis
- Biomarkers, Tumor/analysis
- Bone Marrow Cells
- Gemtuzumab
- Gene Expression Profiling
- Humans
- Multiple Myeloma/drug therapy
- Multiple Myeloma/immunology
- Plasma Cells
- Prognosis
- Sialic Acid Binding Ig-like Lectin 3
Collapse
|